Cathy Bradley
Concepts (501)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Employment | 41 | 2025 | 188 | 10.410 |
Why?
| | Neoplasms | 72 | 2025 | 2884 | 9.520 |
Why?
| | Medicaid | 37 | 2023 | 462 | 7.660 |
Why?
| | Cancer Survivors | 17 | 2025 | 327 | 5.170 |
Why?
| | Breast Neoplasms | 49 | 2024 | 2456 | 5.150 |
Why?
| | Insurance Coverage | 22 | 2024 | 239 | 4.290 |
Why?
| | Medicare | 36 | 2025 | 887 | 3.920 |
Why?
| | Insurance, Health | 20 | 2024 | 303 | 3.570 |
Why?
| | Cost of Illness | 14 | 2024 | 321 | 3.180 |
Why?
| | SEER Program | 22 | 2024 | 224 | 3.090 |
Why?
| | Poverty | 13 | 2022 | 530 | 2.790 |
Why?
| | Medically Uninsured | 12 | 2020 | 129 | 2.440 |
Why?
| | Colorectal Neoplasms | 16 | 2025 | 848 | 2.340 |
Why?
| | Healthcare Disparities | 14 | 2020 | 728 | 2.340 |
Why?
| | United States | 97 | 2025 | 15988 | 2.270 |
Why?
| | Uterine Cervical Neoplasms | 7 | 2020 | 269 | 2.220 |
Why?
| | Health Services Accessibility | 18 | 2024 | 1099 | 2.190 |
Why?
| | Survivors | 17 | 2022 | 520 | 2.070 |
Why?
| | Early Detection of Cancer | 10 | 2024 | 466 | 2.060 |
Why?
| | Medical Oncology | 6 | 2024 | 332 | 1.960 |
Why?
| | Registries | 33 | 2026 | 2385 | 1.840 |
Why?
| | Health Benefit Plans, Employee | 5 | 2022 | 26 | 1.810 |
Why?
| | Antineoplastic Agents | 9 | 2025 | 2197 | 1.760 |
Why?
| | Health Care Costs | 14 | 2024 | 427 | 1.760 |
Why?
| | Humans | 205 | 2026 | 144957 | 1.730 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 6 | 2025 | 1182 | 1.720 |
Why?
| | Survivorship | 4 | 2022 | 54 | 1.560 |
Why?
| | Drug Costs | 4 | 2025 | 116 | 1.500 |
Why?
| | Health Care Reform | 4 | 2021 | 110 | 1.430 |
Why?
| | Lung Neoplasms | 11 | 2025 | 2642 | 1.410 |
Why?
| | Caregivers | 6 | 2023 | 1049 | 1.400 |
Why?
| | Aged | 77 | 2025 | 25947 | 1.270 |
Why?
| | Female | 130 | 2026 | 78376 | 1.250 |
Why?
| | Colonic Neoplasms | 5 | 2016 | 260 | 1.250 |
Why?
| | Policy | 4 | 2024 | 147 | 1.180 |
Why?
| | Prostatic Neoplasms | 11 | 2022 | 978 | 1.170 |
Why?
| | Research | 6 | 2022 | 431 | 1.170 |
Why?
| | Middle Aged | 79 | 2026 | 35928 | 1.160 |
Why?
| | Mental Health | 4 | 2023 | 792 | 1.150 |
Why?
| | Socioeconomic Factors | 20 | 2022 | 1327 | 1.140 |
Why?
| | Michigan | 24 | 2015 | 136 | 1.140 |
Why?
| | Prescription Drugs | 2 | 2023 | 111 | 1.100 |
Why?
| | Income | 8 | 2024 | 202 | 1.080 |
Why?
| | Efficiency | 7 | 2016 | 104 | 1.050 |
Why?
| | Neoplasm Staging | 17 | 2022 | 1465 | 1.040 |
Why?
| | Male | 99 | 2026 | 72406 | 1.030 |
Why?
| | Health Status | 10 | 2013 | 836 | 1.000 |
Why?
| | Aged, 80 and over | 37 | 2025 | 8279 | 0.970 |
Why?
| | Medical Record Linkage | 2 | 2021 | 68 | 0.970 |
Why?
| | Health Status Disparities | 2 | 2023 | 321 | 0.960 |
Why?
| | Papanicolaou Test | 2 | 2017 | 35 | 0.960 |
Why?
| | Adult | 69 | 2026 | 40506 | 0.950 |
Why?
| | Primary Health Care | 6 | 2023 | 1734 | 0.890 |
Why?
| | Motivation | 2 | 2020 | 610 | 0.860 |
Why?
| | Occupational Medicine | 1 | 2024 | 14 | 0.840 |
Why?
| | Safety-net Providers | 3 | 2017 | 126 | 0.840 |
Why?
| | Cancer Care Facilities | 4 | 2024 | 48 | 0.840 |
Why?
| | Medicare Part C | 1 | 2025 | 31 | 0.830 |
Why?
| | Patient Acceptance of Health Care | 4 | 2018 | 886 | 0.810 |
Why?
| | Eligibility Determination | 5 | 2018 | 68 | 0.800 |
Why?
| | Comorbidity | 12 | 2019 | 1660 | 0.780 |
Why?
| | Communication | 3 | 2024 | 967 | 0.780 |
Why?
| | Quality of Life | 8 | 2023 | 3192 | 0.770 |
Why?
| | Colonoscopy | 4 | 2019 | 261 | 0.750 |
Why?
| | Health Expenditures | 8 | 2023 | 194 | 0.750 |
Why?
| | Return to Work | 4 | 2022 | 21 | 0.740 |
Why?
| | Absenteeism | 4 | 2013 | 53 | 0.730 |
Why?
| | Virginia | 7 | 2018 | 55 | 0.700 |
Why?
| | Mass Screening | 10 | 2022 | 1348 | 0.700 |
Why?
| | Occupational Health | 1 | 2024 | 209 | 0.680 |
Why?
| | Focus Groups | 1 | 2024 | 573 | 0.680 |
Why?
| | Medication Adherence | 2 | 2023 | 539 | 0.660 |
Why?
| | Workplace | 4 | 2021 | 274 | 0.660 |
Why?
| | Young Adult | 27 | 2026 | 14126 | 0.660 |
Why?
| | Mammography | 5 | 2024 | 166 | 0.650 |
Why?
| | Cost Sharing | 1 | 2020 | 20 | 0.620 |
Why?
| | Models, Economic | 2 | 2011 | 62 | 0.610 |
Why?
| | Health Equity | 1 | 2022 | 129 | 0.610 |
Why?
| | Information Dissemination | 1 | 2022 | 223 | 0.600 |
Why?
| | Public Health | 1 | 2024 | 566 | 0.590 |
Why?
| | Chemotherapy, Adjuvant | 7 | 2023 | 421 | 0.580 |
Why?
| | Perioperative Care | 1 | 2021 | 231 | 0.580 |
Why?
| | Health Planning Guidelines | 1 | 2018 | 24 | 0.570 |
Why?
| | Preventive Health Services | 5 | 2023 | 154 | 0.570 |
Why?
| | Retirement | 5 | 2022 | 35 | 0.570 |
Why?
| | Health Facilities | 1 | 2019 | 85 | 0.560 |
Why?
| | Spouses | 3 | 2017 | 108 | 0.550 |
Why?
| | Cost-Benefit Analysis | 9 | 2024 | 636 | 0.540 |
Why?
| | Diagnostic Imaging | 1 | 2020 | 339 | 0.540 |
Why?
| | Quality Indicators, Health Care | 1 | 2020 | 335 | 0.540 |
Why?
| | Survival Analysis | 10 | 2019 | 1385 | 0.530 |
Why?
| | Reimbursement, Incentive | 1 | 2017 | 42 | 0.510 |
Why?
| | Healthy People Programs | 1 | 2016 | 7 | 0.490 |
Why?
| | Occupational Health Services | 2 | 2016 | 37 | 0.490 |
Why?
| | Bevacizumab | 1 | 2017 | 167 | 0.470 |
Why?
| | Logistic Models | 13 | 2023 | 2119 | 0.470 |
Why?
| | Job Satisfaction | 3 | 2013 | 240 | 0.470 |
Why?
| | Job Description | 2 | 2013 | 12 | 0.470 |
Why?
| | Triple Negative Breast Neoplasms | 3 | 2023 | 216 | 0.460 |
Why?
| | Massachusetts | 4 | 2021 | 180 | 0.460 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 676 | 0.450 |
Why?
| | Outpatients | 1 | 2019 | 443 | 0.450 |
Why?
| | Length of Stay | 6 | 2012 | 1337 | 0.440 |
Why?
| | Chronic Pain | 1 | 2019 | 292 | 0.440 |
Why?
| | State Government | 3 | 2014 | 46 | 0.430 |
Why?
| | Rectal Neoplasms | 1 | 2016 | 158 | 0.430 |
Why?
| | Fee-for-Service Plans | 4 | 2023 | 98 | 0.430 |
Why?
| | Vaginal Smears | 1 | 2014 | 55 | 0.430 |
Why?
| | Nursing Homes | 4 | 2013 | 172 | 0.420 |
Why?
| | Longitudinal Studies | 11 | 2022 | 2947 | 0.410 |
Why?
| | Health Services Research | 4 | 2010 | 396 | 0.410 |
Why?
| | Mouth Neoplasms | 3 | 2019 | 90 | 0.410 |
Why?
| | Emergency Treatment | 1 | 2015 | 124 | 0.400 |
Why?
| | General Practice | 1 | 2014 | 32 | 0.400 |
Why?
| | Databases, Factual | 8 | 2026 | 1486 | 0.400 |
Why?
| | Risk Factors | 16 | 2026 | 10792 | 0.400 |
Why?
| | Sick Leave | 2 | 2019 | 16 | 0.390 |
Why?
| | Delivery of Health Care | 5 | 2024 | 947 | 0.390 |
Why?
| | Cross-Sectional Studies | 13 | 2023 | 5872 | 0.390 |
Why?
| | Sickness Impact Profile | 1 | 2013 | 62 | 0.380 |
Why?
| | Behavioral Risk Factor Surveillance System | 4 | 2017 | 59 | 0.380 |
Why?
| | Health Personnel | 3 | 2022 | 748 | 0.370 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2015 | 2584 | 0.370 |
Why?
| | Insurance Claim Review | 2 | 2010 | 83 | 0.370 |
Why?
| | Marital Status | 3 | 2007 | 46 | 0.360 |
Why?
| | Value of Life | 2 | 2008 | 19 | 0.360 |
Why?
| | Homes for the Aged | 2 | 2013 | 32 | 0.360 |
Why?
| | Work | 3 | 2010 | 23 | 0.360 |
Why?
| | Cohort Studies | 10 | 2025 | 5965 | 0.360 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1958 | 0.350 |
Why?
| | Age Factors | 11 | 2022 | 3335 | 0.350 |
Why?
| | Colorado | 5 | 2026 | 4564 | 0.350 |
Why?
| | Survival Rate | 7 | 2020 | 2092 | 0.350 |
Why?
| | Neoplasm Metastasis | 3 | 2020 | 695 | 0.330 |
Why?
| | Health Services | 1 | 2012 | 115 | 0.330 |
Why?
| | Periodicals as Topic | 2 | 2023 | 203 | 0.330 |
Why?
| | Patient Protection and Affordable Care Act | 3 | 2024 | 103 | 0.330 |
Why?
| | Hypoglycemia | 1 | 2015 | 477 | 0.320 |
Why?
| | Quality Improvement | 2 | 2018 | 1291 | 0.320 |
Why?
| | Physician Self-Referral | 1 | 2010 | 1 | 0.320 |
Why?
| | Social Class | 4 | 2022 | 268 | 0.320 |
Why?
| | Surgical Procedures, Operative | 2 | 2012 | 271 | 0.320 |
Why?
| | Intestinal Perforation | 3 | 2016 | 44 | 0.310 |
Why?
| | Models, Econometric | 6 | 2017 | 34 | 0.300 |
Why?
| | Financing, Personal | 2 | 2019 | 27 | 0.300 |
Why?
| | Biomedical Research | 2 | 2020 | 710 | 0.300 |
Why?
| | Data Collection | 3 | 2014 | 635 | 0.300 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2019 | 642 | 0.300 |
Why?
| | Waiting Lists | 1 | 2011 | 263 | 0.300 |
Why?
| | Physicians | 1 | 2018 | 940 | 0.300 |
Why?
| | Astrocytoma | 1 | 2010 | 129 | 0.300 |
Why?
| | Radiation Oncology | 1 | 2010 | 89 | 0.300 |
Why?
| | Costs and Cost Analysis | 2 | 2022 | 220 | 0.290 |
Why?
| | Recovery of Function | 1 | 2013 | 710 | 0.290 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2016 | 136 | 0.290 |
Why?
| | Surveys and Questionnaires | 12 | 2018 | 6053 | 0.280 |
Why?
| | Administration, Oral | 2 | 2023 | 848 | 0.280 |
Why?
| | Dentists | 1 | 2008 | 21 | 0.280 |
Why?
| | Persuasive Communication | 1 | 2008 | 14 | 0.280 |
Why?
| | Dental Care | 1 | 2008 | 26 | 0.280 |
Why?
| | Life Expectancy | 1 | 2008 | 72 | 0.280 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2018 | 55 | 0.270 |
Why?
| | Multivariate Analysis | 9 | 2019 | 1540 | 0.270 |
Why?
| | Propensity Score | 1 | 2010 | 367 | 0.270 |
Why?
| | Odds Ratio | 9 | 2014 | 1077 | 0.270 |
Why?
| | Stroke | 3 | 2026 | 1258 | 0.250 |
Why?
| | HIV Infections | 2 | 2022 | 3154 | 0.250 |
Why?
| | Pneumonectomy | 1 | 2008 | 169 | 0.250 |
Why?
| | Patient Education as Topic | 1 | 2011 | 780 | 0.240 |
Why?
| | Confidence Intervals | 4 | 2013 | 333 | 0.240 |
Why?
| | Likelihood Functions | 5 | 2021 | 143 | 0.240 |
Why?
| | Women, Working | 2 | 2002 | 12 | 0.230 |
Why?
| | Quality-Adjusted Life Years | 4 | 2017 | 121 | 0.230 |
Why?
| | Time Factors | 11 | 2013 | 7183 | 0.230 |
Why?
| | Online Systems | 1 | 2005 | 21 | 0.230 |
Why?
| | Depression | 4 | 2021 | 1559 | 0.230 |
Why?
| | Sex Factors | 7 | 2026 | 2114 | 0.230 |
Why?
| | Forecasting | 6 | 2020 | 391 | 0.220 |
Why?
| | Colonic Diseases | 2 | 2016 | 34 | 0.220 |
Why?
| | Disability Evaluation | 1 | 2007 | 310 | 0.220 |
Why?
| | Cost Savings | 2 | 2018 | 86 | 0.220 |
Why?
| | Adolescent | 15 | 2026 | 22453 | 0.220 |
Why?
| | Treatment Outcome | 12 | 2019 | 11695 | 0.220 |
Why?
| | Education, Medical, Graduate | 1 | 2010 | 557 | 0.220 |
Why?
| | Myocardial Infarction | 3 | 2023 | 1209 | 0.220 |
Why?
| | Cross Infection | 2 | 2017 | 262 | 0.210 |
Why?
| | Health Services Needs and Demand | 3 | 2017 | 280 | 0.210 |
Why?
| | Anxiety | 3 | 2021 | 1110 | 0.210 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2011 | 683 | 0.210 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2017 | 249 | 0.200 |
Why?
| | Referral and Consultation | 1 | 2010 | 853 | 0.200 |
Why?
| | Models, Statistical | 4 | 2017 | 682 | 0.200 |
Why?
| | Probability | 5 | 2023 | 312 | 0.200 |
Why?
| | Needs Assessment | 2 | 2024 | 404 | 0.200 |
Why?
| | Head and Neck Neoplasms | 2 | 2019 | 562 | 0.200 |
Why?
| | Hospitals, Public | 1 | 2023 | 30 | 0.200 |
Why?
| | Time-to-Treatment | 1 | 2025 | 245 | 0.200 |
Why?
| | Physician-Patient Relations | 1 | 2008 | 588 | 0.190 |
Why?
| | Community-Based Participatory Research | 1 | 2024 | 166 | 0.190 |
Why?
| | Substance-Related Disorders | 3 | 1997 | 1094 | 0.190 |
Why?
| | Economics, Medical | 1 | 2022 | 6 | 0.190 |
Why?
| | Staphylococcal Infections | 2 | 2017 | 390 | 0.190 |
Why?
| | Hormones | 1 | 2023 | 134 | 0.190 |
Why?
| | Age Distribution | 4 | 2020 | 403 | 0.180 |
Why?
| | Carcinoma | 2 | 2017 | 228 | 0.180 |
Why?
| | Migraine Disorders | 1 | 2024 | 112 | 0.180 |
Why?
| | Salaries and Fringe Benefits | 1 | 2002 | 60 | 0.180 |
Why?
| | Colonic Polyps | 2 | 2014 | 85 | 0.180 |
Why?
| | Health Behavior | 2 | 2019 | 786 | 0.180 |
Why?
| | Risk Assessment | 6 | 2022 | 3676 | 0.180 |
Why?
| | Bisexuality | 1 | 2022 | 39 | 0.180 |
Why?
| | Smoking | 2 | 2019 | 1472 | 0.180 |
Why?
| | Hospital Charges | 3 | 2003 | 46 | 0.180 |
Why?
| | Food Supply | 1 | 2022 | 90 | 0.180 |
Why?
| | Proportional Hazards Models | 5 | 2019 | 1325 | 0.180 |
Why?
| | Ambulatory Care Facilities | 1 | 2024 | 266 | 0.180 |
Why?
| | Incidence | 5 | 2022 | 2883 | 0.170 |
Why?
| | Insulin, Isophane | 1 | 2001 | 22 | 0.170 |
Why?
| | Evidence-Based Medicine | 2 | 2016 | 732 | 0.170 |
Why?
| | Hypoglycemic Agents | 3 | 2018 | 1389 | 0.170 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 1143 | 0.170 |
Why?
| | Intensive Care Units | 2 | 2017 | 916 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 1141 | 0.160 |
Why?
| | Brain Neoplasms | 1 | 2010 | 1322 | 0.160 |
Why?
| | Kentucky | 1 | 2020 | 39 | 0.160 |
Why?
| | Retrospective Studies | 13 | 2024 | 17101 | 0.160 |
Why?
| | Exercise | 3 | 2023 | 2201 | 0.160 |
Why?
| | Homosexuality, Male | 1 | 2022 | 222 | 0.160 |
Why?
| | Internet | 1 | 2005 | 700 | 0.160 |
Why?
| | Decision Making | 2 | 2005 | 980 | 0.160 |
Why?
| | Delayed Diagnosis | 1 | 2020 | 95 | 0.160 |
Why?
| | Sample Size | 1 | 2000 | 123 | 0.150 |
Why?
| | Population Surveillance | 2 | 2022 | 485 | 0.150 |
Why?
| | California | 2 | 2018 | 475 | 0.150 |
Why?
| | Regression Analysis | 5 | 2021 | 1003 | 0.150 |
Why?
| | Hospitalization | 5 | 2016 | 2434 | 0.150 |
Why?
| | Carrier State | 2 | 2017 | 79 | 0.150 |
Why?
| | Benzodiazepines | 1 | 2021 | 168 | 0.150 |
Why?
| | Stress, Psychological | 2 | 2021 | 1153 | 0.150 |
Why?
| | Ownership | 2 | 2010 | 111 | 0.150 |
Why?
| | Language Development Disorders | 1 | 2019 | 40 | 0.150 |
Why?
| | Infection Control | 2 | 2017 | 172 | 0.140 |
Why?
| | Patient Selection | 3 | 2010 | 719 | 0.140 |
Why?
| | Feasibility Studies | 1 | 2023 | 1095 | 0.140 |
Why?
| | Anthracyclines | 3 | 2023 | 47 | 0.140 |
Why?
| | Los Angeles | 2 | 2015 | 76 | 0.140 |
Why?
| | National Cancer Institute (U.S.) | 3 | 2023 | 52 | 0.140 |
Why?
| | Patient Care Team | 1 | 2024 | 689 | 0.140 |
Why?
| | Child | 7 | 2024 | 22657 | 0.140 |
Why?
| | Exercise Therapy | 1 | 2023 | 473 | 0.140 |
Why?
| | Diabetes Mellitus | 3 | 2018 | 1098 | 0.140 |
Why?
| | Taxoids | 3 | 2023 | 116 | 0.140 |
Why?
| | Activities of Daily Living | 2 | 2010 | 441 | 0.140 |
Why?
| | Carboplatin | 1 | 2018 | 160 | 0.140 |
Why?
| | Cetuximab | 1 | 2018 | 111 | 0.140 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2019 | 222 | 0.140 |
Why?
| | Cancer Pain | 1 | 2018 | 36 | 0.140 |
Why?
| | Hyperlipidemias | 1 | 2019 | 122 | 0.140 |
Why?
| | Ireland | 2 | 2016 | 32 | 0.140 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 439 | 0.130 |
Why?
| | Research Design | 4 | 2007 | 1137 | 0.130 |
Why?
| | Infant, Newborn | 4 | 2020 | 6434 | 0.130 |
Why?
| | Unemployment | 2 | 2009 | 42 | 0.130 |
Why?
| | Managed Care Programs | 1 | 2018 | 140 | 0.130 |
Why?
| | Hypertension | 2 | 2024 | 1264 | 0.130 |
Why?
| | Financing, Government | 1 | 2017 | 53 | 0.130 |
Why?
| | Accidental Falls | 1 | 2020 | 222 | 0.130 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 61 | 0.130 |
Why?
| | Public Health Practice | 1 | 2017 | 63 | 0.130 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1268 | 0.130 |
Why?
| | Patient Rights | 2 | 2019 | 11 | 0.130 |
Why?
| | Hospital Costs | 2 | 2011 | 124 | 0.130 |
Why?
| | Inpatients | 2 | 2012 | 546 | 0.130 |
Why?
| | Attitude to Health | 3 | 2019 | 436 | 0.130 |
Why?
| | Psychiatric Department, Hospital | 1 | 1996 | 12 | 0.120 |
Why?
| | Patient Discharge | 1 | 2023 | 983 | 0.120 |
Why?
| | Cisplatin | 1 | 2018 | 334 | 0.120 |
Why?
| | Drug Therapy | 1 | 2017 | 80 | 0.120 |
Why?
| | Sex Distribution | 3 | 2020 | 386 | 0.120 |
Why?
| | Child Behavior | 1 | 1998 | 236 | 0.120 |
Why?
| | Heart Failure | 2 | 2023 | 2323 | 0.120 |
Why?
| | Self Efficacy | 1 | 2019 | 414 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2019 | 502 | 0.120 |
Why?
| | Language | 1 | 2019 | 323 | 0.120 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2016 | 80 | 0.120 |
Why?
| | Smoking Cessation | 1 | 2019 | 439 | 0.110 |
Why?
| | Neonatal Abstinence Syndrome | 1 | 1996 | 27 | 0.110 |
Why?
| | Clinical Competence | 2 | 2014 | 1244 | 0.110 |
Why?
| | Colorectal Surgery | 1 | 2015 | 27 | 0.110 |
Why?
| | Patient Admission | 1 | 1997 | 218 | 0.110 |
Why?
| | Minority Groups | 1 | 2017 | 282 | 0.110 |
Why?
| | Metformin | 1 | 2018 | 319 | 0.110 |
Why?
| | Residence Characteristics | 2 | 2008 | 378 | 0.110 |
Why?
| | Child, Preschool | 4 | 2020 | 11799 | 0.110 |
Why?
| | Case-Control Studies | 4 | 2024 | 3608 | 0.110 |
Why?
| | Follow-Up Studies | 6 | 2019 | 5417 | 0.100 |
Why?
| | Mastectomy, Segmental | 3 | 2009 | 108 | 0.100 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 194 | 0.100 |
Why?
| | Child Development | 1 | 2019 | 484 | 0.100 |
Why?
| | National Health Programs | 1 | 2014 | 23 | 0.100 |
Why?
| | Pennsylvania | 2 | 2024 | 138 | 0.100 |
Why?
| | Patient Satisfaction | 2 | 2013 | 705 | 0.100 |
Why?
| | Autism Spectrum Disorder | 1 | 2019 | 412 | 0.100 |
Why?
| | Systems Integration | 1 | 2013 | 36 | 0.100 |
Why?
| | Infant | 3 | 2020 | 10039 | 0.100 |
Why?
| | Bridged-Ring Compounds | 2 | 2023 | 31 | 0.100 |
Why?
| | Health Status Indicators | 1 | 2014 | 166 | 0.100 |
Why?
| | Cerebrovascular Disorders | 1 | 2014 | 103 | 0.100 |
Why?
| | Computer Simulation | 2 | 2023 | 1026 | 0.100 |
Why?
| | Helping Behavior | 1 | 2013 | 20 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 3 | 2021 | 966 | 0.100 |
Why?
| | Pilot Projects | 3 | 2021 | 1890 | 0.090 |
Why?
| | Quality of Health Care | 2 | 2008 | 693 | 0.090 |
Why?
| | Medical Audit | 1 | 2013 | 77 | 0.090 |
Why?
| | Occupations | 1 | 2012 | 51 | 0.090 |
Why?
| | Mandatory Programs | 1 | 2012 | 16 | 0.090 |
Why?
| | Intensive Care Units, Neonatal | 1 | 1996 | 279 | 0.090 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2012 | 24 | 0.090 |
Why?
| | Pregnancy, Unwanted | 1 | 2012 | 15 | 0.090 |
Why?
| | Maryland | 3 | 1997 | 66 | 0.090 |
Why?
| | Life Tables | 2 | 2008 | 21 | 0.090 |
Why?
| | Prospective Studies | 3 | 2017 | 7997 | 0.090 |
Why?
| | Cost Control | 1 | 2012 | 37 | 0.090 |
Why?
| | Cause of Death | 1 | 2014 | 472 | 0.090 |
Why?
| | Goals | 2 | 2023 | 184 | 0.090 |
Why?
| | Self Disclosure | 1 | 2011 | 62 | 0.090 |
Why?
| | Community Health Services | 1 | 2013 | 234 | 0.090 |
Why?
| | Contraceptive Agents, Female | 1 | 2012 | 80 | 0.090 |
Why?
| | Educational Status | 1 | 2013 | 467 | 0.090 |
Why?
| | Contraception Behavior | 1 | 2012 | 108 | 0.090 |
Why?
| | Retreatment | 1 | 2011 | 77 | 0.080 |
Why?
| | Sepsis | 1 | 2017 | 641 | 0.080 |
Why?
| | Video Recording | 1 | 2011 | 213 | 0.080 |
Why?
| | Mental Disorders | 2 | 1997 | 1172 | 0.080 |
Why?
| | Economics, Nursing | 1 | 2010 | 1 | 0.080 |
Why?
| | Mastectomy | 1 | 2011 | 162 | 0.080 |
Why?
| | Interinstitutional Relations | 1 | 2010 | 53 | 0.080 |
Why?
| | Insulin | 1 | 2001 | 2507 | 0.080 |
Why?
| | Stress, Physiological | 1 | 2013 | 453 | 0.080 |
Why?
| | Access to Information | 1 | 2010 | 48 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2014 | 589 | 0.080 |
Why?
| | Pregnancy Complications | 1 | 1996 | 592 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2010 | 3415 | 0.080 |
Why?
| | Sentinel Surveillance | 1 | 2009 | 46 | 0.080 |
Why?
| | Consumer Behavior | 1 | 1990 | 70 | 0.080 |
Why?
| | Bone Marrow Transplantation | 1 | 2011 | 294 | 0.080 |
Why?
| | Standard of Care | 1 | 2010 | 80 | 0.080 |
Why?
| | Insurance Claim Reporting | 1 | 2009 | 26 | 0.080 |
Why?
| | Ohio | 1 | 2009 | 145 | 0.070 |
Why?
| | Occult Blood | 1 | 2009 | 40 | 0.070 |
Why?
| | Private Sector | 1 | 2009 | 50 | 0.070 |
Why?
| | Women's Health | 2 | 2012 | 310 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2013 | 582 | 0.070 |
Why?
| | Comparative Effectiveness Research | 1 | 2010 | 170 | 0.070 |
Why?
| | Physical Exertion | 1 | 2010 | 207 | 0.070 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2009 | 70 | 0.070 |
Why?
| | Bias | 1 | 2010 | 202 | 0.070 |
Why?
| | Linear Models | 1 | 2011 | 854 | 0.070 |
Why?
| | Home Nursing | 1 | 2008 | 23 | 0.070 |
Why?
| | Reimbursement Mechanisms | 1 | 2009 | 80 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2026 | 2925 | 0.070 |
Why?
| | Sex Characteristics | 2 | 2022 | 791 | 0.070 |
Why?
| | Prevalence | 2 | 2020 | 2836 | 0.070 |
Why?
| | Psychometrics | 1 | 2013 | 734 | 0.070 |
Why?
| | Education, Professional | 1 | 2008 | 18 | 0.070 |
Why?
| | Health Care Surveys | 1 | 2010 | 539 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 372 | 0.070 |
Why?
| | Pain | 2 | 2010 | 782 | 0.070 |
Why?
| | Radiotherapy | 1 | 2008 | 206 | 0.070 |
Why?
| | Self Care | 1 | 2010 | 389 | 0.060 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 529 | 0.060 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 923 | 0.060 |
Why?
| | Leukemia | 1 | 2008 | 245 | 0.060 |
Why?
| | Cognition Disorders | 1 | 2010 | 538 | 0.060 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2006 | 143 | 0.060 |
Why?
| | Lung Diseases | 1 | 2012 | 787 | 0.060 |
Why?
| | Charities | 1 | 2005 | 13 | 0.060 |
Why?
| | Empirical Research | 1 | 2005 | 21 | 0.050 |
Why?
| | Hospice Care | 1 | 2007 | 220 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2001 | 3890 | 0.050 |
Why?
| | Diagnosis-Related Groups | 1 | 2003 | 35 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 1721 | 0.050 |
Why?
| | Florida | 2 | 2014 | 117 | 0.050 |
Why?
| | Resource Allocation | 1 | 2003 | 53 | 0.050 |
Why?
| | Pandemics | 2 | 2022 | 1695 | 0.050 |
Why?
| | Health Surveys | 2 | 2007 | 518 | 0.050 |
Why?
| | Causality | 1 | 2023 | 126 | 0.050 |
Why?
| | Social Security | 1 | 2002 | 5 | 0.050 |
Why?
| | Selection Bias | 1 | 2002 | 38 | 0.050 |
Why?
| | Markov Chains | 2 | 2017 | 129 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 722 | 0.050 |
Why?
| | Sampling Studies | 1 | 2002 | 99 | 0.050 |
Why?
| | Mastectomy, Radical | 1 | 2001 | 4 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2005 | 901 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2002 | 108 | 0.040 |
Why?
| | Insulin, Long-Acting | 1 | 2001 | 65 | 0.040 |
Why?
| | Family Characteristics | 1 | 2002 | 197 | 0.040 |
Why?
| | Insulin Glargine | 1 | 2001 | 88 | 0.040 |
Why?
| | Arrhythmias, Cardiac | 1 | 2023 | 361 | 0.040 |
Why?
| | Normal Distribution | 1 | 2000 | 22 | 0.040 |
Why?
| | Drug Evaluation | 1 | 2000 | 79 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 927 | 0.040 |
Why?
| | Diffusion of Innovation | 1 | 2001 | 98 | 0.040 |
Why?
| | Nursing Research | 1 | 2000 | 53 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 1054 | 0.040 |
Why?
| | Presenteeism | 1 | 2019 | 6 | 0.040 |
Why?
| | Palliative Care | 1 | 2007 | 1008 | 0.040 |
Why?
| | Etidronic Acid | 1 | 1998 | 3 | 0.040 |
Why?
| | Alendronate | 1 | 1998 | 14 | 0.040 |
Why?
| | Federal Government | 1 | 2018 | 23 | 0.040 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 1998 | 40 | 0.040 |
Why?
| | Informed Consent | 1 | 2000 | 198 | 0.030 |
Why?
| | Spinal Fractures | 1 | 1998 | 73 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2021 | 457 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 15 | 0.030 |
Why?
| | Smoking Prevention | 1 | 1998 | 166 | 0.030 |
Why?
| | Lymph Node Excision | 1 | 2019 | 173 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2019 | 334 | 0.030 |
Why?
| | Estrogen Replacement Therapy | 1 | 1998 | 144 | 0.030 |
Why?
| | Tennessee | 1 | 2017 | 54 | 0.030 |
Why?
| | Hyperglycemia | 1 | 2001 | 375 | 0.030 |
Why?
| | Puberty | 1 | 1998 | 140 | 0.030 |
Why?
| | Ecosystem | 1 | 2022 | 589 | 0.030 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 1997 | 40 | 0.030 |
Why?
| | Patient Isolation | 1 | 2017 | 20 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2018 | 239 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2017 | 183 | 0.030 |
Why?
| | Utilization Review | 1 | 1996 | 39 | 0.030 |
Why?
| | Arizona | 1 | 1996 | 81 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 783 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 2017 | 68 | 0.030 |
Why?
| | Patient Dropouts | 1 | 1997 | 65 | 0.030 |
Why?
| | Schools | 1 | 2000 | 453 | 0.030 |
Why?
| | Anticholesteremic Agents | 1 | 2018 | 154 | 0.030 |
Why?
| | Catheter-Related Infections | 1 | 2017 | 94 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2017 | 69 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2018 | 182 | 0.030 |
Why?
| | Health Policy | 1 | 2019 | 401 | 0.030 |
Why?
| | Alzheimer Disease | 1 | 2002 | 622 | 0.030 |
Why?
| | Hospitals, Community | 1 | 1996 | 65 | 0.030 |
Why?
| | Obstetric Labor, Premature | 1 | 1996 | 39 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 509 | 0.030 |
Why?
| | Health Resources | 2 | 2009 | 130 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2018 | 511 | 0.030 |
Why?
| | Protoporphyrins | 1 | 1993 | 14 | 0.030 |
Why?
| | Telemedicine | 1 | 2023 | 948 | 0.030 |
Why?
| | Learning Curve | 1 | 2014 | 70 | 0.020 |
Why?
| | Acute Disease | 1 | 1996 | 1031 | 0.020 |
Why?
| | Lead | 1 | 1993 | 70 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1718 | 0.020 |
Why?
| | Sensitivity and Specificity | 3 | 2009 | 1990 | 0.020 |
Why?
| | Calcium | 1 | 1998 | 1184 | 0.020 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 601 | 0.020 |
Why?
| | Community Participation | 1 | 2013 | 132 | 0.020 |
Why?
| | Societies, Medical | 1 | 2016 | 887 | 0.020 |
Why?
| | Risk | 1 | 2014 | 911 | 0.020 |
Why?
| | Gastroenterology | 1 | 2014 | 189 | 0.020 |
Why?
| | General Surgery | 1 | 2014 | 207 | 0.020 |
Why?
| | Pregnancy | 2 | 2012 | 7191 | 0.020 |
Why?
| | Work Capacity Evaluation | 1 | 2010 | 11 | 0.020 |
Why?
| | Hepatitis B | 1 | 1991 | 66 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2013 | 465 | 0.020 |
Why?
| | Contraception | 1 | 2012 | 170 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4293 | 0.020 |
Why?
| | Budgets | 1 | 2009 | 14 | 0.020 |
Why?
| | Sigmoidoscopy | 1 | 2009 | 15 | 0.020 |
Why?
| | Leadership | 1 | 2013 | 409 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2010 | 198 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2009 | 174 | 0.020 |
Why?
| | Prostatectomy | 1 | 2009 | 93 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2013 | 603 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 551 | 0.020 |
Why?
| | Occupational Exposure | 1 | 1991 | 354 | 0.020 |
Why?
| | Psychology | 1 | 2008 | 88 | 0.020 |
Why?
| | Demography | 1 | 2008 | 288 | 0.020 |
Why?
| | Lifting | 1 | 2006 | 4 | 0.010 |
Why?
| | Least-Squares Analysis | 1 | 2006 | 76 | 0.010 |
Why?
| | Illinois | 1 | 2006 | 47 | 0.010 |
Why?
| | Mortality | 1 | 2008 | 376 | 0.010 |
Why?
| | Telephone | 1 | 2007 | 175 | 0.010 |
Why?
| | Body Weight | 1 | 1990 | 978 | 0.010 |
Why?
| | Patient Compliance | 1 | 2009 | 589 | 0.010 |
Why?
| | Prejudice | 1 | 2006 | 60 | 0.010 |
Why?
| | Myocardial Revascularization | 1 | 2003 | 85 | 0.010 |
Why?
| | Burnout, Professional | 1 | 2010 | 484 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 427 | 0.010 |
Why?
| | Vaccination | 1 | 1991 | 1423 | 0.010 |
Why?
| | Behavior | 1 | 2002 | 91 | 0.010 |
Why?
| | Episode of Care | 1 | 2001 | 7 | 0.010 |
Why?
| | Decision Trees | 1 | 2001 | 81 | 0.010 |
Why?
| | Drug Prescriptions | 1 | 2002 | 285 | 0.010 |
Why?
| | Cardiac Catheterization | 1 | 2003 | 560 | 0.010 |
Why?
| | Reoperation | 1 | 2001 | 631 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2002 | 1137 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 1998 | 1048 | 0.010 |
Why?
| | Estrogens | 1 | 1998 | 380 | 0.010 |
Why?
| | Estradiol | 1 | 1998 | 533 | 0.010 |
Why?
| | Lead Poisoning | 1 | 1993 | 17 | 0.010 |
Why?
| | Reference Values | 1 | 1993 | 798 | 0.010 |
Why?
| | ROC Curve | 1 | 1993 | 615 | 0.010 |
Why?
| | Program Evaluation | 1 | 1991 | 949 | 0.000 |
Why?
|
|
Bradley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|